KNTC1 knockdown inhibits the proliferation and migration of osteosarcoma cells by MCM2.
KNTC1
MCM2
osteosarcoma
proliferation
Journal
Molecular carcinogenesis
ISSN: 1098-2744
Titre abrégé: Mol Carcinog
Pays: United States
ID NLM: 8811105
Informations de publication
Date de publication:
31 May 2024
31 May 2024
Historique:
revised:
26
04
2024
received:
25
10
2023
accepted:
07
05
2024
medline:
31
5
2024
pubmed:
31
5
2024
entrez:
31
5
2024
Statut:
aheadofprint
Résumé
Osteosarcoma (OS) is a common primary malignant bone tumor, and it is necessary to further investigate the molecular mechanism of OS progression. The expression of kinetochore associated protein 1 (KNTC1) and minichromosome maintenance 2 (MCM2) was detected by immunohistochemistry, quantitative PCR (qPCR) and Western blot. Gene knockdown or overexpression cell models were constructed and the proliferation, apoptosis, cell cycle and migration were detected in vitro, besides, xenograft models were established to explore the effects of KNTC1 downregulation in vivo. Public databased and bioinformatics analysis were performed to screen the downstream molecules and determine the expression of MCM2 in cancers. KNTC1 was overexpressed in OS tissues and positively correlated with overall survival of OS patients. KNTC1 knockdown inhibited the proliferation and migration, and arrested G2 phase, and induced apoptosis. Besides, KNTC1 downregulation restricted the xenograft tumor formation. MCM2, one of the coexpressed genes, was highly expressed in sarcoma and downregulated after KNTC1 knockdown. MCM2 overexpression heightened the proliferation and migration ability of OS cells, which was reversed the inhibiting effects of KNTC1 knockdown. KNTC1 was overexpressed in OS and promoted the progression of OS by upregulating MCM2.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : The Cadre Health Care Projects of the Sichuan Provincial Health and Health Committee
ID : CGB2023089
Organisme : The Key Projects of Sichuan Provincial Department of Science and Technology
ID : 2021YFS0268
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Ghafouri‐Fard S, Shirvani‐Farsani Z, Hussen BM, Taheri M. The critical roles of lncRNAs in the development of osteosarcoma. Biomed Pharmacother. 2021;135:111217.
Chong ZX, Yeap SK, Ho WY. Unraveling the roles of miRNAs in regulating epithelial‐to‐mesenchymal transition (EMT) in osteosarcoma. Pharmacol Res. 2021;172:105818.
Bielack S, Carrle D, Casali PG. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow‐up. Ann Oncol. 2009;20(suppl 4):iv137‐iv139.
Lallier M, Marchandet L, Moukengue B, et al. Molecular chaperones in osteosarcoma: diagnosis and therapeutic issues. Cells. 2021;10(4):754.
Chen Y, Liu R, Wang W, et al. Advances in targeted therapy for osteosarcoma based on molecular classification. Pharmacol Res. 2021;169:105684.
Kim T. Recent progress on the localization of PLK1 to the kinetochore and its role in mitosis. Int J Mol Sci. 2022;23(9):5252.
Wei J, Xia S, Sun A, et al. Geranylgeranylation signaling promotes breast cancer cell mitosis via the YAP‐activated transcription of kinetochore/centromere genes. Am J Cancer Res. 2022;12(3):1143‐1155.
Pan W, Wang S, Liu X, et al. KNTC1, regulated by HPV E7, inhibits cervical carcinogenesis partially through Smad2. Exp Cell Res. 2023;423(1):113458.
Chan GKT, Jablonski SA, Starr DA, Goldberg ML, Yen TJ. Human Zw10 and ROD are mitotic checkpoint proteins that bind to kinetochores. Nat Cell Biol. 2000;2(12):944‐947.
Liu R, Liu R, Guo Z, et al. shRNA‑mediated knockdown of KNTC1 inhibits non‐small‐cell lung cancer through regulating PSMB8. Cell Death Dis. 2022;13(8):685.
Shen S, Kong J, Qiu Y, Yang X, Wang W, Yan L. Identification of core genes and outcomes in hepatocellular carcinoma by bioinformatics analysis. J Cell Biochem. 2019;120(6):10069‐10081.
Liu CT, Min L, Wang YJ, Li P, Wu YD, Zhang S. T. shRNA‑mediated knockdown of KNTC1 suppresses cell viability and induces apoptosis in esophageal squamous cell carcinoma. Int J Oncol. 2019;54(3):1053‐1060.
Bleichert F, Botchan MR, Berger JM. Mechanisms for initiating cellular DNA replication. Science. 2017;355(6327):eaah6317.
Sun Y, Cheng Z, Liu S. MCM2 in human cancer: functions, mechanisms, and clinical significance. Mol Med. 2022;28(1):128.
Tang Z, Yang Y, Chen W, Li E, Liang T. Demethylation at enhancer upregulates MCM2 and NUP37 expression predicting poor survival in hepatocellular carcinoma patients. J Transl Med. 2022;20(1):49.
Yang S, Kim CY, Hwang S, et al. COEXPEDIA: exploring biomedical hypotheses via co‐expressions associated with medical subject headings (MeSH). Nucleic Acids Res. 2017;45(D1):D389‐D396.
Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA‐ceRNA, miRNA‐ncRNA and protein‐RNA interaction networks from large‐scale CLIP‐Seq data. Nucleic Acids Res. 2014;42:D92‐D97.
Chandrashekar DS, Karthikeyan SK, Korla PK, et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18‐27.
Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649‐658.
Qin Q, Ramesh S, Gomez‐Salazar M, et al. CNTNAP4 signaling regulates osteosarcoma disease progression. npj Precision Oncology. 2023;7(1):2.
Liu L, Chen H, Chen X, Yao C, Shen W, Jia C. KNTC1 as a putative tumor oncogene in pancreatic cancer. J Cancer Res Clin Oncol. 2022;149(7):3023‐3031.
Huang H, Fan X, Qiao Y, Yang M, Ji Z. Knockdown of KNTC1 inhibits the proliferation, migration and tumorigenesis of human bladder cancer cells and induces apoptosis. Crit Rev Eukaryot Gene Expr. 2021;31(1):49‐60.
Zhengxiang Z, Yunxiang T, Zhiping L, Zhimin Y. KNTC1 knockdown suppresses cell proliferation of colon cancer. 3 Biotech. 2021;11(6):262.
Tong H, Liu X, Peng C, Shen B, Zhu Z. Silencing of KNTC1 inhibits hepatocellular carcinoma cells progression via suppressing PI3K/Akt pathway. Cellular Signalling. 2023;101:110498.
Wang C, Wang Y, Liu C, Meng X, Hang Z. Kinetochore‐associated protein 1 promotes the invasion and tumorigenicity of cervical cancer cells via matrix metalloproteinase‐2 and matrix metalloproteinase‐9. Bioengineered. 2022;13(4):9495‐9507.
Zhang J, Wang J, Wu J, Huang J, Lin Z, Lin X. UBE2T regulates FANCI monoubiquitination to promote NSCLC progression by activating EMT. Oncol Rep. 2022;48(2):139.
Zheng P, Li L. FANCI cooperates with IMPDH2 to promote lung adenocarcinoma tumor growth via a MEK/ERK/MMPs pathway. Onco Targets Ther. 2020;13:451‐463.
Guerrero‐Puigdevall M, Fernandez‐Fuentes N, Frigola J. Stabilisation of half MCM ring by Cdt1 during DNA insertion. Nat Commun. 2021;12(1):1746.
Shi Q, Li S, Lyu Q, Zhang S, Bai Y, Ma J. Hypoxia inhibits cell cycle progression and cell proliferation in brain microvascular endothelial cells via the miR‐212‐3p/MCM2 axis. Int J Mol Sci. 2023;24(3):2788.
Li S, Liu H, Liu W, et al. ESRG is critical to maintain the cell survival and self‐renewal/pluripotency of hPSCs by collaborating with MCM2 to suppress p53 pathway. Int J Biol Sci. 2023;19(3):916‐935.
Yuan J, Lan H, Huang D, et al. Multi‐Omics analysis of MCM2 as a promising biomarker in pan‐cancer. Front Cell Dev Biol. 2022;10:852135.
Zhou J, Wang M, Zhou Z, Wang W, Duan J, Wu G. Expression and prognostic value of MCM family genes in osteosarcoma. Front Mol Biosci. 2021;8:668402.
Jia W, Wang C. KNTC1 and MCM2 are the molecular targets of gallbladder cancer. Aging. 2023;15(14):7008‐7022.
Zhang J, Zhang H, Wang Y, Wang Q. MCM2‐7 in clear cell renal cell carcinoma: MCM7 promotes tumor cell proliferation. Front Oncol. 2021;11:782755.
Hsu EC, Shen M, Aslan M, et al. MCM2‐7 complex is a novel druggable target for neuroendocrine prostate cancer. Sci Rep. 2021;11(1):13305.